OCMS Bio, LLC
OCMS Bio is an antibody discovery and engineering company focused on improving health outcomes of patients globally through rapid discovery and optimization of the best possible antibody drugs. They leverage AI-driven drug discovery and function-first antibody selection to deliver better, faster breakthroughs. The company is committed to bringing safer, more efficacious, and more convenient medicines to patients worldwide.
Industries
Nr. of Employees
small (1-50)
OCMS Bio, LLC
3700 Horizon Drive, Suite 170, King of Prussia, PA 19406
Products
Antibody candidate OB-24-01 (Respiratory Syncytial Virus)
Preclinical antibody candidate in proof-of-concept and IND-enabling stages targeting RSV.
Antibody candidate OB-24-02 (ActRIIA/B — human metabolism)
Preclinical antibody program targeting ActRIIA/B pathways related to human metabolism.
Antibody candidate OB-25-01 (Undisclosed — Orphan Drug)
Preclinical antibody program designated as an orphan indication (undisclosed target).
Antibody candidate OB-25-02 (Undisclosed — Oncology ADC)
Preclinical antibody program intended for oncology, described as an antibody–drug conjugate (ADC) program (undisclosed target).
Antibody candidate OB-24-01 (Respiratory Syncytial Virus)
Preclinical antibody candidate in proof-of-concept and IND-enabling stages targeting RSV.
Antibody candidate OB-24-02 (ActRIIA/B — human metabolism)
Preclinical antibody program targeting ActRIIA/B pathways related to human metabolism.
Antibody candidate OB-25-01 (Undisclosed — Orphan Drug)
Preclinical antibody program designated as an orphan indication (undisclosed target).
Antibody candidate OB-25-02 (Undisclosed — Oncology ADC)
Preclinical antibody program intended for oncology, described as an antibody–drug conjugate (ADC) program (undisclosed target).
Services
Discovery and screening of antibody candidates using cell-based, function-first high-throughput workflows that preserve native heavy–light chain pairing and enable direct functional assessment of large variant libraries.
Advancement of preclinical antibody assets toward clinical readiness, including program strategy and IND-enabling activities to prepare candidates for regulatory submission.
Discovery and screening of antibody candidates using cell-based, function-first high-throughput workflows that preserve native heavy–light chain pairing and enable direct functional assessment of large variant libraries.
Advancement of preclinical antibody assets toward clinical readiness, including program strategy and IND-enabling activities to prepare candidates for regulatory submission.
Expertise Areas
- Antibody discovery and engineering
- AI-driven antibody design
- Mammalian cell–based high-throughput screening
- Function‑first screening and functional assay development
Key Technologies
- AI-designed de novo antibody libraries
- Mammalian cell-based high-throughput screening
- Function-first on-cell antibody screening
- Preservation of native heavy–light chain pairing
News & Updates
Dr. Nikitin bringing extensive experience in biopharmaceutical development.
The company’s selection at Biotech Showcase provides a platform to showcase its latest advancements.
Dr. Ramdev Puligedda presented groundbreaking research highlighting the company’s use of AI in monoclonal antibody discovery.
OCMS Bio's expansion to a new facility in King of Prussia boosts antibody research and preclinical pipeline.
Dr. Nikitin bringing extensive experience in biopharmaceutical development.
The company’s selection at Biotech Showcase provides a platform to showcase its latest advancements.
Dr. Ramdev Puligedda presented groundbreaking research highlighting the company’s use of AI in monoclonal antibody discovery.
OCMS Bio's expansion to a new facility in King of Prussia boosts antibody research and preclinical pipeline.